Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

Banerjee S, Brown A, McGahan L, Asakawa K, Hutton B, Clark M, Severn M, Sharma M, Cox JL
Record ID 32010001766
English
Authors' recommendations: In patients with ACS without ST-segment elevation, therapy with clopidogrel and ASA was more efficacious than ASA alone, with an increased risk of major bleeding. A post hoc analysis of patients with PVD showed that there was a reduction in MI favouring clopidogrel plus ASA compared with ASA alone and an increased risk of minor bleeding. The economic analysis found that at a willingness-to-pay threshold of $50,000 per QALY, for patients with a mean age of 60 years at the time of the initial event or PVD diagnosis, treatment options that included clopidogrel were the most cost-effective compared with ASA alone for the secondary prevention of vascular events. In patients with ACS, clopidogrel plus ASA was found to be most cost-effective. For patients with PVD, clopidogrel alone was the most cost-effective. As the mean age of patients with PVD increases, clopidogrel plus ASA becomes most costeffective for patients with PVD as well.
Details
Project Status: Completed
URL for project: http://www.cadth.ca/media/pdf/H1481_Clopidogrel_vs_Antiplatetel_Agents_tr_e.pdf
Year Published: 2010
URL for published report: http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/2708
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Acute Coronary Syndrome
  • Adult
  • Myocardial Infarction
  • Platelet Aggregation Inhibitors
  • Ticlopidine
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.